Charles Owen

CAREER SUMMARY

I am a PhD scientist with over 18 years pharmaceutical industry experience. I have significant experience of both drug discovery and development; from target discovery to lead optimisation, early development, biomarker strategy, clinical development, regulatory filings and post-marketing activities.

EPSILON BIOCONSULTING

July 2014 – date

Providing consulting services to biotechnology and pharmaceutical industry.
Specific expertise in:

- Discovery & development of therapeutic antibodies and other biologics
- Novel modes of administration of biologics
- Respiratory disease area strategy and portfolio review
- Scientific support to clinical development and commercial teams, especially in fields of allergy, asthma, and other inflammatory diseases

NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH

April 1996-June 2014

Novartis Horsham Research Centre, Horsham, West Sussex, UK.

ASTHMA BIOLOGICS PORTFOLIO PRE-CLINICAL LEAD

2009-2014

Novartis Institutes for BioMedical Research lead representative for asthma biologics global project teams with responsibility for all pre-clinical research activities including:

- Regulatory submissions / interactions (IND, IMPD, Health Authority submissions documentation including approvals (EU, FDA, PMDA), Paediatric Investigational Plans etc)
- Key development experience of projects including:

Omalizumab (Xolair) – anti-IgE mAb: Ph2 (1998) – Post-marketing support (2014).

- Responsible for EU/ FDA/PMDA pharmacology submissions for asthma.
- Core member of Global Project Team in collaboration with Genentech.
- Key responsibilities included: biomarker strategy, Point of Care diagnostics; member of commercial/medical affairs team developing scientific story.

Ligelizumab (QGE031 – 2006-2014) – high-affinity anti-IgE mAb (Ph2 asthma)

- Leader of in-licensing and project integration teams with Tanox Inc.
- Core member of Global Clinical Trial and Global Project Teams.
- Core member of project development and commercial strategy teams across indications.
- Responsible for project biomarker and personalised medicine strategy.

QAX576 (anti-IL-13 mAb): 2011-2014:

- Core member of Global Project and Global Clinical Strategy Teams
- Responsible for project biomarker strategy
- Key author and member of regulatory strategy team

Secukinumab (anti-IL-17a in severe asthma – PoC): 2011-2014

QBX258 (Undisclosed anti-cytokine combination therapy)

Member of expert panels:

- Asthma disease stratification and biomarker review.
- Anti-IgE commercial strategy review and scientific narrative development.
- Respiratory business development & licensing strategy review.

Cross disease area and cross-indication experience and expertise including: severe asthma, atopic dermatitis, chronic urticaria, nasal polyposis, eosinophilic esophagitis, food allergy and ulcerative skin disease.

PULMONARY DELIVERY OF BIOLOGICS STRATEGY LEADER

2008 – 2014

Developed and led initiatives aimed at improving antibody delivery to the lung. This included working with cross-functional teams to investigate:

- Pulmonary delivery of proteins, antibodies and peptides
  - Initiative included investigating antibody disposition and distribution following pulmonary delivery as nebulised solution or dry powder
  - The use of isolated perfused lung technology
  - Investigating the compatibility of antibody format with dry powder technology
- Targeted delivery of proteins and antibodies to the lung through transcytotic mechanisms
  - Work involved demonstrating proof of concept – antibody transport across endothelial cells
  - The use of isolated perfused lung technology in rat
  - Use of phage technology in vivo to isolate novel transcytotic mechanisms

PROJECT TEAM LEADER

2000 – 2009

Highly experienced drug discovery and development scientist with proven track-record of delivering drugs ready for clinical development. Extensive experience of leading multiple cross-disciplinary project teams conducting new drug discovery.
My achievements include:

- Taking >10 targets from concept to full project lead discovery, including CRTH2 antagonist (QAW039) – now in Ph2.
- > 10 yrs experience of leading large multi-disciplinary teams of up to 40 chemists, biologists and computational scientists.
- Track-record: delivered 7 drug candidates into early development, and 4 drugs into human clinical studies.

LABORATORY DIRECTOR

1996 – 2006

Responsible for a laboratory of molecular cell biologists and immunologists.

OTHER RELEVANT EXPERIENCE

- Member of Respiratory Franchise Business Development and Licensing team.
- Member of Respiratory Diseases therapeutic area strategy team.
- Published over 30 scientific papers and patents.
- Regular speaker at allergy and respiratory disease meetings and congresses.

Postdoctoral Fellow: (1992 – 1996)
Cancer Research UK (London): Transcriptional regulation of the murine surfeit gene locus.

PhD (1989-1992)
University of Glasgow: Transcriptional regulation of bacteriophage phiC31 repressor proteins

MBA (2005)

Warwick Business School: Dissertation: Measuring productivity in innovation-led industries.

PERSONAL DETAILS

Date of Birth: 19th December 1966
Status: Married with 2 children
Contact: Email: Charlie@epsilonbioconsulting.co.uk